TITLE

Role of EGFR mutations in the pathogenesis of lung adenocarcinomas

AUTHOR(S)
Ali, M.
PUB. DATE
January 2006
SOURCE
Thorax;Jan2006, Vol. 61 Issue 1, p16
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the role of epidermal growth factor receptor (EGFR) mutations in the pathogenesis of lung adenocarcinomas. In a study, the authors collected surgically resected tissue specimens from 20 patients with adenocarcinomas and one with adenosquamous carcinoma, all with EGFR gene mutations. Out of 21 patients with mutant lung adenocarcinomas nine were found to have identical EGFR mutations in normal epithelium foci within the tumour. The study found that EGFR mutations in normal respiratory epithelium were more frequent within the tumour than in adjacent sites.
ACCESSION #
20089474

 

Related Articles

  • Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Sonobe, M.; Manabe, T.; Wada, H.; Tanaka, F. // British Journal of Cancer;8/8/2005, Vol. 93 Issue 3, p355 

    Epidermal growth factor receptor (EGFR) mutations are a potential predictor of the effectiveness of EGFR inhibitors for the treatment of lung cancer. Although EGFR mutations were reported to occur with high frequency in nonsmoking Japanese adenocarcinoma patients, the exact nature has not been...

  • Gefitinib or Carboplatin�Paclitaxel in Pulmonary Adenocarcinoma. Mok, Tony S.; Yi-Long Wu; Thongprasert, Sumitra; Chih-Hsin Yang; Da-Tong Chu; Saijo, Nagahiro; Sunpaweravong, Patrapim; Han, Baohui; Margono, Benjamin; Ichinose, Yukito; Nishiwaki, Yutaka; Ohe, Yuichiro; Yang, Jin-Ji; Chewaskulyong, Busyamas; Jiang, Haiyi; Duffield, Emma L.; Watkins, Claire L.; Armour, Alison A.; Fukuoka, Masahiro // New England Journal of Medicine;9/3/2009, Vol. 361 Issue 10, p947 

    Background: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non�small-cell lung cancer. Methods: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had...

  • Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma. Jin, Bo; Dong, Yu; Wang, Hui-min; Huang, Jin-su; Han, Bao-hui // Acta Pharmacologica Sinica;Mar2014, Vol. 35 Issue 3, p373 

    Aim:To evaluate the relationship between epidermal growth factor receptor (EGFR) mutations and serum carcinoembryonic antigen (CEA) levels in Chinese nonsmokers with pulmonary adenocarcinoma.Methods:We sequenced exons 18-21 of the EGFR gene in 98 cases. The patients were divided into two groups...

  • EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Smits, Alexander; Kummer, J.; Hinrichs, John; Herder, Gerarda; Scheidel-Jacobse, Karen; Jiwa, N.; Ruijter, T.; Nooijen, Peet; Looijen-Salamon, Monica; Ligtenberg, Marjolijn; Thunnissen, Frederik; Heideman, Daniëlle; Weger, Roel; Vink, Aryan // Cellular Oncology (2211-3428);Jun2012, Vol. 35 Issue 3, p189 

    Background: Frequencies of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) have predominantly been determined in East Asian and North American populations, showing large differences between these populations. The aim of the present study was to determine the frequency of EGFR and...

  • Membrane-bound estrogen receptor-α expression and epidermal growth factor receptor mutation are associated with a poor prognosis in lung adenocarcinoma patients. Shimizu, Katsuhiko; Hirami, Yuji; Saisho, Shinsuke; Yukawa, Takuro; Maeda, Ai; Yasuda, Koichiro; Nakata, Masao // World Journal of Surgical Oncology;2012, Vol. 10 Issue 1, p141 

    Background: The purpose of this study is to clarify the correlations between the expression of membrane-bound estrogen receptor-α (mERα) and epidermal growth factor receptor (EGFR) mutation and clinicopathological factors, especially in relation to the prognosis, in patients with lung...

  • EGFR mutations and the terminal respiratory unit. Yatabe, Yasushi // Cancer & Metastasis Reviews;Mar2010, Vol. 29 Issue 1, p23 

    Considerable knowledge has accumulated about mutations of the epidermal growth factor receptor (EGFR)-tyrosine kinase domain since these were first identified in 2004. Patients with nonsmall cell lung cancer with this mutation show dramatic clinical responses to treatment with EGFR-tyrosine...

  • Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Suda, Kenichi; Tomizawa, Kenji; Mitsudomi, Tetsuya // Cancer & Metastasis Reviews;Mar2010, Vol. 29 Issue 1, p49 

    KRAS and epidermal growth factor receptor ( EGFR) are the two most frequently mutated proto-oncogenes in adenocarcinoma of the lung. The occurrence of these two oncogenic mutations is mutually exclusive, and they exhibit many contrasting characteristics such as clinical background, pathological...

  • The correlation between EGFR mutation status and the risk of brain metastasis in patients with lung adenocarcinoma. Li, Bo; Sun, Suo-zhu; Yang, Ming; Shi, Jian-ling; Xu, Wei; Wang, Xi-fan; Song, Mao-min; Chen, Huo-ming // Journal of Neuro-Oncology;Aug2015, Vol. 124 Issue 1, p79 

    To explore the correlation between epidermal growth factor receptor (EGFR) mutation status and the risk of brain metastasis (BM) in patients with lung adenocarcinoma, the clinical data of 100 patients with pathologically confirmed lung adenocarcinoma and known EGFR mutation status at exon 18,...

  • Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. Smith, G. D.; Chadwick, B. E.; Willmore-Payne, C.; Bentz, J. S. // Journal of Clinical Pathology;Apr2008, Vol. 61 Issue 4, p487 

    Background: Activating epidermal growth factor receptor (EGFR) mutations have been implicated in non-small cell lung cancer (NSCLC), and have also been clinically correlated with patient sensitivity to targeted EGFR inhibitors. Aim: To describe a technique for determining EGFR mutation status on...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics